

22nd ADVAC

ADVANCED COURSE OF VACCINOLOGY

Les Pensières
Center for Global Health
Veyrier-du-Lac, France

9-20 May 2022

Application deadline:
15 November 2021

CONTACT:

E-mail: advac@unige.ch

Website: www.advac.org

ADVAC is a two-week training programme for decision-makers, including academia, industry, governmental and non-governmental agencies. The Course aims to facilitate critical decision-making in vaccinology by providing participants with a comprehensive overview of the various aspects of vaccinology (immunology, vaccine development, clinical trials, regulatory processes, vaccine-specific issues including new vaccines, vaccination strategies and policies, programme implementation, humanitarian emergencies, social, economic, political and ethical issues, financing, and communications...)

Registration for the course will open on the website (www.advac.org) on **July 1, 2021** and will close on **November 15, 2021**.

21 SUCCESSFUL YEARS

75 PARTICIPANTS

80 INTERNATIONAL SPEAKERS

13 INTERACTIVE SESSIONS

11 DAYS OF KNOWLEDGE-SHARING

INTERACTIVE GROUP SESSIONS & CASE STUDIES

1 DIPLOMA AND CME CERTIFICATE

A NETWORK OF OVER 1,200 ALUMNI

The 2020 edition of ADVAC was cancelled due to the COVID crisis and the 2021 edition was exceptionally held virtually as a live interactive event.

Organized by

The Mérieux Foundation
and University of Geneva



**UNIVERSITÉ
DE GENÈVE**



With the co-sponsorship of

- Bill & Melinda Gates Foundation
- Centers for Disease Control and Prevention (CDC)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- European Centre for Disease Prevention and Control (ECDC)
- European & Developing Countries Clinical Trials and Controls (EDCTP)
- European Society for Paediatric Infectious Diseases (ESPID)
- Mérieux Foundation
- Johns Hopkins Bloomberg School of Public Health
- National Foundation for Infectious Diseases (NFID)
- National Institutes of Health (NIH/NIAID-USA) and Fogarty International Center
- World Health Organization

Education grants are provided by

- Coalition for Epidemic Preparedness Innovations (CEPI)
- GlaxoSmithKline (GSK)
- Janssen Vaccines & Prevention B.V.
- Merck
- Pfizer
- Sanofi Pasteur
- Serum Institute of India
- Takeda

